WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014194991) PHARMACEUTICAL FORMULATIONS COMPRISING AGOMELATINE IN THE FORM OF AGOMELATINE CO-CRYSTAL WITH AN ORGANIC ACID
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/194991    International Application No.:    PCT/EP2014/001409
Publication Date: 11.12.2014 International Filing Date: 24.05.2014
IPC:
A61K 31/165 (2006.01), A61K 47/12 (2006.01), A61P 25/20 (2006.01), A61P 25/22 (2006.01), A61P 25/24 (2006.01)
Applicants: ZENTIVA, K.S. [CZ/CZ]; U Kabelovny 130 102 37 Praha 10 (CZ)
Inventors: REZAC, Jaroslav; (CZ).
NOVAK, Martin; (CZ).
PRIBYL, Daniel; (CZ).
HANOVSKA, Anna; (CZ).
RIDVAN, Ludek; (CZ).
DUMICIC, Aleksandra; (HR).
KRAL, Vladimir; (CZ)
Agent: JIROTKOVA, Ivana; Rott, Ruzicka & Guttmann P.O. Box 44 120 00 Praha 2 (CZ)
Priority Data:
13002931.7 06.06.2013 EP
Title (EN) PHARMACEUTICAL FORMULATIONS COMPRISING AGOMELATINE IN THE FORM OF AGOMELATINE CO-CRYSTAL WITH AN ORGANIC ACID
(FR) FORMULATIONS PHARMACEUTIQUES COMPRENANT DE L'AGOMÉLATINE SOUS LA FORME D'UN CO-CRISTAL D'AGOMÉLATINE AVEC UN ACIDE ORGANIQUE
Abstract: front page image
(EN)A pharmaceutical formulation, comprising agomelatine in the form of agomelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatine dose per one dosage unit and at least one pharmaceutically acceptable excipient for effective treatment of diseases responsive to therapy by agomelatine.
(FR)La présente invention concerne une formulation pharmaceutique comprenant de l'agomélatine sous la forme d'un co-cristal d'agomélatine avec un agent formateur de co-cristal sélectionné dans le groupe des acides organiques en une quantité correspondant à 15 à 22 mg de dose d'agomélatine par unité posologique et au moins un excipient pharmaceutiquement acceptable pour le traitement efficace de maladies qui répondent à un traitement par l'agomélatine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)